# Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

> **NCT01023256** · PHASE1,PHASE2 · COMPLETED · sponsor: **MorphoSys AG** · enrollment: 96 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MOR103
- **DRUG:** MOR103
- **DRUG:** MOR103

## Key facts

- **NCT ID:** NCT01023256
- **Lead sponsor:** MorphoSys AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01023256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01023256, "Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01023256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*